DSIJ Mindshare

Lupin gets approval for atorvastatin calcium tablets
Shohini Nath
/ Categories: Trending, DSIJ News

Lupin gets approval for atorvastatin calcium tablets

Lupin has received approval for its Atorvastatin Calcium Tablets from the US drug regulator.

 

The United States Food and Drug Administration (USFDA) has given their approval for USP, 10 mg, 20 mg, 40 mg, and 80 mg to Lupin to market the tablets in the US.

 

Lupin's Atorvastatin Calcium Tablets, is the generic version of Pfizer Inc's Lipitor Tablets, 10 mg, 20 mg, 40 mg and 80 mg. It is indicated to lower cholesterol levels in blood for adults and children aged over 10 years. Atorvastatin is also prescribed to lower the risk for heart attack, stroke in patients with cardiovascular diseases. It also works to lower the risk of diabetes and other risk factors such as eye problems, kidney diseases or high BP.

 

Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg reported annual sales of approximately US$696 million in the US.

 

Lupin is involved in developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

 

The shares of Lupin on Friday opened at Rs. 799.80 per share against Thursday’s close of Rs. 791. At  hours, the shares were trading at Rs 790.05, down by 0.13 per cent. The stock hit an intraday high of Rs. 799.80 and an intraday low of Rs. 789.75 per share on the BSE. The 52-week high stood at Rs. 986 and the 52-week low was Rs 723.55 per share on the BSE.

 

Meanwhile, Sensex was quoting 36,636.96 level, down by 0.30 per cent

Previous Article VA Tech Wabag secures Clean Ganga order of Rs. 575 crore
Next Article Ten stocks close to their 52-weeks high
Print
1109 Rate this article:
5.0
Please login or register to post comments.
DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR